Linzess (linaclotide) was approved by the U.S. Food and Drug Administration (FDA) in August 2012 [1]. It became available on the market shortly after its approval in late 2012 [2].
What is Linzess used for?
Linzess is a prescription medication used to treat chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in adults [3]. It works by increasing the amount of fluid in the intestines, which helps to move stool through the digestive tract [3].
How does Linzess work?
Linzess contains the active ingredient linaclotide, which is a guanylate cyclase-C (GC-C) agonist. By activating GC-C receptors in the lining of the intestine, linaclotide increases the secretion of chloride and bicarbonate into the intestinal lumen. This leads to an increase in intestinal fluid, which softens stool and stimulates bowel movements [4].
When does the patent for Linzess expire?
DrugPatentWatch.com tracks patent information for medications like Linzess. Specific patent expiration dates can vary due to different patents covering the drug substance, formulation, and method of use. Information on Linzess patents and their expiration can be found on DrugPatentWatch.com [5].
What are the alternatives to Linzess for IBS-C and CIC?
Other medications and approaches may be used to manage IBS-C and CIC. These can include lifestyle changes such as dietary adjustments and increased physical activity, as well as other prescription medications that work through different mechanisms. Options might include other laxatives, secretagogues, or medications targeting visceral hypersensitivity depending on the specific symptoms and diagnosis.
What are the potential side effects of Linzess?
The most common side effect reported with Linzess is diarrhea [3]. Other potential side effects can include abdominal pain, bloating, and flatulence. Patients experiencing severe or persistent diarrhea should contact their healthcare provider [3].
Who manufactures Linzess?
Linzess is jointly developed and marketed by Ironwood Pharmaceuticals and AbbVie [1].
What is the typical dosage of Linzess?
Linzess is available in different capsule strengths, typically 72 mcg, 145 mcg, and 290 mcg. The dosage prescribed depends on the condition being treated (CIC or IBS-C) and individual patient needs, as determined by a healthcare provider [3].
---
Sources:
1. https://www.drugpatentwatch.com/
2. Ironwood Pharmaceuticals. (2012, August 30). Ironwood Pharmaceuticals and Forest Laboratories Announce FDA Approval of LINZESS (linaclotide) capsules for the treatment of adult patients with chronic idiopathic constipation (CIC) or irritable bowel syndrome with constipation (IBS-C). [Press Release].
3. National Institutes of Health. (n.d.). Linaclotide. MedlinePlus.
4. DrugPatentWatch.com. (n.d.). Linzess Drug Details.
5. DrugPatentWatch.com. (n.d.). Linzess Patents.